pSivida completes recruitment of European Pancreatic Cancer Study and releases preliminary findings
Preliminary data are very encouraging. Eight weeks follow-up data available on the first 10 patients treated shows 90% of these patients have had either stabilization or reduction in size of their primary tumor and none of these patients experienced product related significant adverse events. Preliminary data on the balance of the patients treated will be released when a minimum of eight weeks follow-up data have been obtained. The first analysis of all the patients is expected to be available at the end of the calendar year and results will be used to guide future studies.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.